Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.
about
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Prevalence and type distribution of human papillomavirus infection in women from North Sardinia, ItalyFood webs in the human body: linking ecological theory to viral dynamics.Concurrence of multiple human papillomavirus infections in a large US population-based cohort.High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy.Impact of vaccination on 14 high-risk HPV type infections: a mathematical modelling approach.Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.Papillomaviruses: Viral evolution, cancer and evolutionary medicineVaccine-relevant human papillomavirus (HPV) infections and future acquisition of high-risk HPV types in men.HIV Infection Alters the Spectrum of HPV Subtypes Found in Cervical Smears and Carcinomas from Kenyan Women.A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.Order of HPV/Chlamydia infections and cervical high-grade precancer risk: a case-cohort study.Clinical trials of human papillomavirus vaccines and beyond.Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).
P2860
Q33953881-E5B88C6D-46E5-429A-B021-9B8FE053D889Q34046723-E42BEACC-ECEB-42D0-9571-ED8DE000495BQ34479094-3D279567-4EFA-46C1-946A-CCB8E8A4EC6FQ34553582-9A4D2D93-FFCD-425B-955B-5E3B52C39434Q34744071-C233185B-64E3-4BBC-8748-BFA223112E9EQ34979497-789DC056-7E0E-41C3-AF44-0251CCFCC589Q35117498-C472E069-CCB4-4FA5-B2A0-3CA8140C57B7Q35166924-032BCA72-CAFF-4A6E-92A1-C1DD8EAE5357Q36379269-0BD8DAE7-5BB1-4965-90E5-CF917BC3F7A3Q36675916-113AA69F-0447-43B8-8113-08EE9EA5C188Q37366649-643C9133-C8D5-47B4-A7F0-BF62AC73CA33Q37846849-A22AD918-6688-4FDF-8804-38E415D676CAQ38111962-97E599AF-4D72-41FB-821A-A5E4390869C9Q44170367-B7DD47BE-04A1-4377-BE40-AF229D4090F2Q47603242-F2C80DF4-D9F4-4498-9235-C8AF4C5511E9
P2860
Differences in incidence and co-occurrence of vaccine and nonvaccine human papillomavirus types in Finnish population before human papillomavirus mass vaccination suggest competitive advantage for HPV33.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Differences in incidence and c ...... mpetitive advantage for HPV33.
@en
Differences in incidence and c ...... mpetitive advantage for HPV33.
@nl
type
label
Differences in incidence and c ...... mpetitive advantage for HPV33.
@en
Differences in incidence and c ...... mpetitive advantage for HPV33.
@nl
prefLabel
Differences in incidence and c ...... mpetitive advantage for HPV33.
@en
Differences in incidence and c ...... mpetitive advantage for HPV33.
@nl
P2093
P2860
P356
P1476
Differences in incidence and c ...... mpetitive advantage for HPV33.
@en
P2093
Johanna Palmroth
Marjo Kaasila
Marko Merikukka
Matti Lehtinen
Proscovia B Namujju
Reinhard Kirnbauer
P2860
P304
P356
10.1002/IJC.25675
P577
2010-11-28T00:00:00Z